ライフサイエンスコーパス: creatine kinase

1 ere modeled in the C terminus of muscle-type creatine kinase.

2 pyruvate kinase muscle isozyme, isoforms of creatine kinase.

3 pomyosin, myosin or an isoform of the enzyme creatine kinase.

4 d pathology and reduction in levels of serum creatine kinase.

5 ors make neurotransmission less dependent on creatine kinase.

6 ith significant reduction in levels of serum creatine kinase.

7 ins such as myosin heavy chain fast type and creatine kinase.

8 roximal weakness and markedly elevated serum creatine kinase.

9 kinase and 427 with only the MB fraction of creatine kinase.

10 causing pain or cramping or increasing serum creatine kinase.

11 ficulties, and normal to moderately elevated creatine kinase.

12 aminotransferase, lactate dehydrogenase, and creatine kinase.

13 thesis from OXPHOS, anaerobic glycolysis and creatine kinase.

14 assessed by cardiac enzymes, troponin I, and creatine kinase.

15 table for bulky ASB9 substrates, such as the creatine kinases.

16 ut preinfarction angina (n=166) by both peak creatine kinase (1094+/-75 IU/L versus 2270+/-102 IU/L;

17 d in 9 healthy men (mean age 27.9 y, SE 3.3; creatine kinase 115 to 859 IU/L, median 358), was associ

18 Exogenous creatine kinase (500 to 4000 IU/L, phosphocreatine 5 mM)

19 e fibers, increased central nuclei, elevated creatine kinase activity and endomysial fibrosis.

20 fat, cold exposure stimulates mitochondrial creatine kinase activity and induces coordinated express

21 further explore the effect of calmodulin on creatine kinase activity and show that it is increased b

22 in which both oxidative phosphorylation and creatine kinase activity are inhibited.

23 imus lumborum and a 5-fold increase in serum creatine kinase activity compared with healthy male litt

24 on and reduced the vascular adenylate kinase/creatine kinase activity ratio essential for the respons

25 l muscle health in mdx mice, reducing plasma creatine kinase activity, an established measure of musc

26 on of inflammatory markers of muscle damage (creatine kinase activity, C-reactive protein, proinflamm

27 e, as evidenced by i) normal levels of serum creatine kinase activity, ii) a lack of Evans blue dye u

28 ontractile function and a reduction in serum creatine kinase activity.

29 d skeletal muscle mass and normalized plasma creatine kinase activity.

30 dependence of infarct size plotting the peak creatine kinase against time onset of ischemia.

31 lar to enolase, pyruvate kinase, isoforms of creatine kinase, aldolase A and an isoform of glyceralde

32 nin, 538 MIs were identified versus 327 with creatine kinase and 427 with only the MB fraction of cre

33 ease above the number of MIs identified with creatine kinase and a 41% (95% CI, 37% to 46%) increase

34 ne blood chemistry was normal, as were serum creatine kinase and aldolase levels and thyroid, hepatic

35 ngs to the phosphagen kinase family of which creatine kinase and arginine kinase are the typical repr

36 Maximum creatine kinase and creatine kinase-MB values declined (

37 e cell number, and a decrease in activity of creatine kinase and several oxidative enzymes.

38 ult onset muscular dystrophy with high serum creatine kinase and that mutation screening, particularl

39 rast-enhanced cardiac MRI (CMRI; day 3+/-1), creatine kinase and troponin I area-under-the-curve, and

40 Apart from transient elevations of creatine kinase and troponin, microemboli can be visuali

41 revascularization report reduced release of creatine kinase and troponin.

42 ervations of immobilization of mitochondrial creatine kinase and type I hexokinase on biological memb

43 derived from lactate dehydrogenase, one from creatine kinase, and four from serum albumin protein.

44 , Minnesota coding of the ECG, and troponin, creatine kinase, and its MB fraction measured simultaneo

45 f three model proteins (Human Serum Albumin, creatine kinase, and myoglobin).

46 ge, sex, and admission levels of troponin I, creatine kinase, and N-terminal pro-brain natriuretic pe

47 f such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke di

48 5 IU/L versus 2270+/-102 IU/L; P<0.0001) and creatine kinase area under curve (18 420+/-18 941 versus

49 terquartile range, 14-42; P<0.01) and median creatine kinase areas under the curve were 22 000 and 38

50 with serum muscle enzyme levels (P<0.05 for creatine kinase, aspartate aminotransferase, and aldolas

51 variability compared with the commonly used creatine kinase assay, and correlated better with the re

52 revealed that they have close similarity to creatine kinase B (CKB) isoforms, heterogeneous nuclear

53 inding protein, we identified it to be brain creatine kinase (B-CK).

54 e levels of creatine kinase, MB isoenzyme of creatine kinase, blood urea nitrogen, creatinine, K(+) i

55 sed guanidinoacetate N-methyltransferase and creatine kinase, both at the protein and RNA levels, and

56 These miRNAs convergently target creatine kinase, brain-type (CKB), which phosphorylates

57 A 43 kDa band, identified as creatine kinase by proteomic analysis, showed the potent

58 ce of isotopically enriched magnesium on the creatine kinase catalyzed phosphorylation of adenosine d

59 ription, and QI 3 = complete blood count and creatine kinase check every 6 months for gout patients r

60 s critical role in hair bundle function, the creatine kinase circuit is essential for high-sensitivit

61 Peak creatine kinase (CK(peak)) and the rate of CK increase a

62 Serial creatine kinase (CK) and CKMB or troponin measurements w

63 We find two major proteins, creatine kinase (CK) and glyceraldehyde-3-phosphate dehy

64 after exposure to in vitro oxidative stress: creatine kinase (CK) and glyceraldehyde-3-phosphate dehy

65 (MI) changed to rely on troponin rather than creatine kinase (CK) and its MB fraction (CK-MB).

66 kinases of known structure (the homodimeric creatine kinase (CK) and the monomeric arginine kinase (

67 s, but, to date, has not been confirmed with creatine kinase (CK) assays.

68 In comparing the level and activity of creatine kinase (CK) between wild-type and MuRF1 Tg(+) h

69 utilization networks in response to chronic creatine kinase (CK) deficiency, a hallmark of cardiovas

70 In the 14-day study, serum creatine kinase (CK) dropped by 50%, which was not seen

71 f the absolute level and rate of increase of creatine kinase (CK) elevation after primary percutaneou

72 iated with simvastatin-induced myopathy with creatine kinase (CK) elevation.

73 describe an imaging method that employs the creatine kinase (CK) gene as a marker of donor hepatocyt

74 Creatine kinase (CK) is a commonly used biomarker to ass

75 Creatine kinase (CK) is a member of a family of phosphor

76 n the anti-Jo-1 antibody level and the serum creatine kinase (CK) level, as well as muscle and joint

77 Creatine kinase (CK) levels are increased on dried blood

78 a 2-tiered approach to NBS with screening by creatine kinase (CK) levels in dried blood spots followe

79 Serum creatine kinase (CK) levels were lower (p = 0.025), and

80 In addition, serum creatine kinase (CK) levels within the Oxford CMS cohort

81 Anti-HMGCR levels, creatine kinase (CK) levels, and strength were assessed

82 ovascular death or nonfatal MI, defined as a creatine kinase (CK) MB fraction of at least 100 ng/mL o

83 We measured myocardial creatine kinase (CK) metabolite concentrations and adeno

84 iation of a recently reported variant in the creatine kinase (CK) muscle gene, CKM Glu83Gly (rs115590

85 ATP production rate constants (k(f)) through creatine kinase (CK) or ATP synthase (ATPase) with 2 spe

86 The creatine kinase (CK) reaction plays a critical role in s

87 Tissue injury was assessed by creatine kinase (CK) released and determination of cell

88 The creatine kinase (CK) system is thought to play an integr

89 lationship between cTnT, cardiac troponin I, creatine kinase (CK), CK-myocardial band levels, and ske

90 tions, and measurements of serum cTnT, cTnI, creatine kinase (CK), creatine kinase myocardial band (C

91 Another phosphagen kinase, creatine kinase (CK), is found in sponges, cnidarians, a

92 a showing reduced metabolism through cardiac creatine kinase (CK), the major myocardial energy reserv

93 enosine triphosphate (ATP) synthesis through creatine kinase (CK), the primary myocardial energy rese

94 or decreased intracellular ATP generation by creatine kinase (CK), the prime energy reserve of the he

95 Inhibition of creatine kinase (CK), which increases cytosolic ADP, in

96 Creatine treatment enhanced cell fusion in a creatine kinase (CK)-dependent manner suggesting that AT

97 ATP that is synthesized locally from PCr via creatine kinase (CK).

98 defined as: 1) new Q-wave and MB isoform of creatine kinase (CK-MB) elevation (daily electrocardiogr

99 Studies evaluating mortality and creatine kinase (CK-MB), troponin, or both were included

100 ir of high-energy phosphate (HEP) bonds, and creatine kinases (CK) catalyze the transfer of HEP from

101 Gower score, time to run 30 feet, and serum creatine kinase [CK] level) and with nonquantitative MR

102 s, we identified that brain-type cytoplasmic creatine kinase (Ckb) was greatly induced in mature oste

103 identified the ATP-buffering, mitochondrial creatine kinase CKMT1 as necessary for survival of EVI1-

104 The present study identifies creatine kinases (CKs), key metabolic enzymes for rapid

105 e dye uptake into muscle and increased serum creatine kinase compared to the 129T2/SvEmsJ background.

106 he most common adverse event was an elevated creatine kinase concentration to more than ten times the

107 ical and functional changes using the muscle creatine kinase conditional frataxin knockout (KO) mouse

108 Ablation of Vps34 in the heart of muscle creatine kinase-Cre;Vps34(f/f) mice led to cardiomegaly

109 Peak and area under the creatine kinase curve did not differ between both groups

110 mechanical overload, which decreased muscle creatine kinase-driven TEAD-1 transgene expression, and

111 ound that Ckb was the predominant isoform of creatine kinase during osteoclastogenesis.

112 on and the contribution of other isoforms of creatine kinase during RANKL-induced osteoclastogenesis

113 different than control in terms of myalgia, creatine kinase elevation, cancer, and discontinuations

114 , gastrointestinal effects, and asymptomatic creatine kinase elevation.

115 tin at its highest doses was associated with creatine kinase elevations (odds ratio, 4.14; 95% credib

116 00 patients [RD], 2.7; 95% CI, -3.2 to 8.7), creatine kinase elevations (RD, 0.2; 95% CI, -0.6 to 0.9

117 omyolysis is rare, muscle symptoms and serum creatine kinase elevations are sufficiently frequent dur

118 ransaminase elevations, but not of myalgias, creatine kinase elevations, rhabdomyolysis, or withdrawa

119 rapy versus placebo; and reports of myalgia, creatine kinase elevations, rhabdomyolysis, transaminase

120 ese symptoms may occur with or without serum creatine kinase elevations.

121 was the forward rate constant (k(f)) of the creatine kinase enzyme in the frontal lobe.

122 Reduced kf of the creatine kinase enzyme is consistent with an abnormality

123 (STOMP) study assessed symptoms and measured creatine kinase, exercise capacity, and muscle strength

124 3 and miR-551a expression, which derepresses creatine kinase expression and allows energy to be captu

125 Creatine kinase expression falls, possibly impairing hig

126 common grade 3-4 adverse events were raised creatine kinase (five [6%] in the 200 mg group vs 19 [13

127 ne kinase reaction, we have now measured the creatine kinase forward reaction rate constant in BD.

128 We found a significant reduction in creatine kinase forward reaction rate constant in the BD

129 hy control participants at 4T and quantified creatine kinase forward reaction rate constant using (31

130 ants or isoforms of tropomyosin, arginine or creatine kinase, glyceraldehyde-3-phosphate dehydrogenas

131 R, 2.620; 95% CI, 1.073-6.399; P = .035) and creatine kinase (>800 U/L; OR, 2.328; 95% CI, 1.129-4.80

132 In human muscle creatine kinase (HMCK) this residue, Cys283, forms part

133 Consistent with this model, inhibition of creatine kinase in avascular retinas blocks synaptic tra

134 on by OXPHOS (vOX), anaerobic glycolysis and creatine kinase in moderate and severe intensity exercis

135 here was a significant increase in mean peak creatine kinase in the oxygen group compared with the no

136 value exceeded 10 times normal, but average creatine kinase increased 20.8+/-141.1 U/L (P<0.0001) wi

137 ant bundle protein; at approximately 0.5 mM, creatine kinase is capable of maintaining high ATP level

138 Creatine kinase is unique among marker genes, because it

139 This concept is applied here to creatine kinase isoenzyme (CK-MB), a cardiac biomarker i

140 stically significant (P = .003) reduction in creatine kinase kf was observed in SZ.

141 resonance-determined myocardial salvage and creatine kinase kinetics.

142 y hearing as demonstrated by hearing loss in creatine kinase knockout mice.

143 Serum creatine kinase level can be normal or only mildly eleva

144 After exercise, at an endogenous creatine kinase level of 4664, ADP-induced platelet aggr

145 borns for Duchenne muscular dystrophy by the creatine kinase level on dried blood spots.

146 -year history of weight loss and an elevated creatine kinase level up to 4000 U/L.

147 The median creatine kinase level was 5326 U/L.

148 = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 t

149 Infarct size was measured as the peak creatine kinase level, a metric supported in a subgroup

150 ntractures, severe scoliosis, elevated serum creatine kinase level, myopathic electrodiagnostic chang

151 ed lactic acidosis and mild elevation of the creatine kinase level.

152 ecificity had proximal weakness (100%), high creatine kinase levels (mean maximum 10,333 IU/liter), a

153 Decreased serum creatine kinase levels (significant improvement for all

154 d by adult onset muscle weakness, high serum creatine kinase levels and a prominent inflammatory infi

155 cle degeneration, but had no effect on serum creatine kinase levels and muscle strength.

156 , Evans blue dye uptake is reduced and serum creatine kinase levels are lower.

157 These programs used elevated creatine kinase levels in dried blood spots for the init

158 Elevated creatine kinase levels in the neonatal period are the in

159 Myopathy--muscle pain or weakness with blood creatine kinase levels more than ten times the upper lim

160 ociated with an increased incidence of serum creatine kinase levels that were more than 10 times the

161 ntral nucleation, tissue fibrosis, and serum creatine kinase levels were dramatically reduced in Sgcd

162 muscle histology, in vitro muscle force, and creatine kinase levels were measured.

163 Circulating creatine kinase levels were significantly lower in mice

164 Serum creatine kinase levels were usually moderately high (mea

165 thy characterized by mildly increased plasma creatine kinase levels, a variation in myofibre size and

166 ephaly, severe hypotonia with elevated blood creatine kinase levels, and early fatal outcome.

167 distribution and significantly reduced serum creatine kinase levels, but had limited effect on muscle

168 of Dmdmdx-5Cv mice results in reduced serum creatine kinase levels, improved sarcolemmal integrity,

169 ake, increased muscle fibre necrosis, plasma creatine kinase levels, muscle PDK4, muscle atrophy F-bo

170 is was associated with greatly reduced serum creatine kinase levels, near-normal histology, and funct

171 lder ages, chronic remodeling and increasing creatine kinase levels.

172 ced interstitial fibrosis and elevated serum creatine kinase levels.

173 was accompanied by a significant decrease in creatine kinase levels.

174 Evans blue dye infiltration and lower serum creatine kinase levels.

175 bdominal pain, and moderately elevated serum creatine kinase levels.

176 diffusing capacity for carbon monoxide, and creatine kinase levels.

177 etermined by muscle histopathology and serum creatine kinase levels.

178 neutral protease calpain activity and plasma creatine kinase levels.

179 e histology, running performance, and plasma creatine kinase levels.

180 not associated with persistent elevations in creatine kinase levels.

181 diographic changes, and troponin rather than creatine kinase levels.

182 e disorder associated with elevated neonatal creatine kinase levels.

183 esonance imaging, and through elevated serum creatine kinase levels.

184 We monitored serum creatine kinase levels; changes in peak cycle work, oxyg

185 globin and somatic cytochrome-C) and others (creatine kinase M, malate dehydrogenase cytosolic, fibri

186 Fractional synthesis rate (FSR) of plasma creatine kinase M-type (CK-M) and carbonic anhydrase 3 (

187 e cell apoptosis and reduced serum levels of creatine kinase M.

188 protein expression of creatine kinase-mt and creatine kinase-m isoforms was significantly reduced in

189 00 fg/ml troponin T, creatine kinase MM, and creatine kinase MB in serum.

190 ved hemodynamics and decreased the levels of creatine kinase, MB isoenzyme of creatine kinase, blood

191 similar or lower in HBOC than HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine

192 Serum creatine kinase-MB (CK-MB) and cardiac troponin T (cTnT)

193 Creatine kinase-MB (CK-MB) and cardiac troponins (cTn) a

194 (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB), and TnI and BNP by CART.

195 similar information as a value of 5x ULN for creatine kinase-MB (hazard ratio, 4.31; 99% confidence i

196 No significant changes in creatine kinase-MB and troponin-I were seen.

197 l-resistant patients had higher incidence of creatine kinase-MB elevation than the respective sensiti

198 PMI was defined as creatine kinase-MB isoenzyme level > or = 10x upper limi

199 re hemodynamic deterioration, preangiography creatine kinase-MB isoenzyme rise >2 x normal, and time

200 (cardiac troponin I level > or =0.7 ng/mL or creatine kinase-MB level > or =5.0 ng/mL and/or diagnost

201 images provided equal performance, and peak creatine kinase-MB levels correlated with MRI infarct si

202 Postprocedural cTnT and creatine kinase-MB mass levels (ULN, 6.7 ng/mL in men an

203 There was no increase in creatine kinase-MB or troponin associated with the adven

204 Troponin-T and creatine kinase-MB peaked at day 1 after procedure (both

205 Maximum creatine kinase and creatine kinase-MB values declined (5.2% and 7.6%; P<0.0

206 43; P=0.003 and hazard ratio per doubling of creatine kinase-MB, 1.30; 95% confidence interval, 1.05-

207 ity C-reactive protein (hs-CRP), Troponin-T, creatine kinase-MB, fibrinogen, and D-Dimer concentratio

208 n the activity of creatine phosphokinase and creatine kinase-MB.

209 models and included haptoglobin, IL-10, and creatine kinase-MB.

210 utcome information as a cutoff of 5x ULN for creatine kinase-MB.

211 an HEX pigs, but creatine kinase-MB (but not creatine kinase-MB/creatine kinase ratio) was higher wit

212 function, and perfusion), injury biomarkers (creatine-kinase-MB and troponin I), and histopathologic

213 Studies using the muscle creatine kinase (MCK) conditional frataxin knockout mous

214 inol-binding protein (hRBP) under the muscle creatine kinase (MCK) promoter (MCKhRBP) with the PKCdel

215 ified a conserved sequence within the Muscle creatine kinase (MCK) promoter that is critical for high

216 t overexpress Rad in muscle using the muscle creatine kinase (MCK) promoter-enhancer.

217 gnize the MPEX control element in the Muscle creatine kinase (MCK) promoter.

218 ch nebulin deletion was driven by the muscle creatine kinase (MCK) promotor.

219 (ACh) receptor (alpha-AChR), desmin, muscle creatine kinase (MCK), myosin heavy chain (MHC) isoforms

220 ke signaling in this process, we used muscle creatine kinase (MCK)-Cre to disrupt expression of insul

221 omatic gene transfer or transgenesis (muscle creatine kinase [MCK]-EcSOD) in mice significantly atten

222 -activated receptor alpha (PPARalpha; muscle creatine kinase [MCK]-PPARalpha) or PPARbeta/delta (MCK-

223 on of the tyrosine phosphatase SHP-2 (muscle creatine kinase [MCK]-SHP-2 null) exhibited a reduction

224 5:00 am onset of reperfusion, with the peak creatine kinase measured at the peak of the curve being

225 n of total reverse T3, high concentration of creatine kinase, mild anaemia), and radiological (thicke

226 st notably the regions harboring CKMT2 gene (creatine kinase, mitochondrial 2) and RASGRF2 gene (Ras

227 ltiplexed detection of 100 fg/ml troponin T, creatine kinase MM, and creatine kinase MB in serum.

228 The BZ protein expression of creatine kinase-mt and creatine kinase-m isoforms was si

229 Interaction between mitochondrial creatine kinase (MtCK) and adenine nucleotide translocas

230 ts, there was a reduction in serum levels of creatine kinase muscle-brain isoenzyme, a myocardial-spe

231 Prespecified secondary outcome measures of creatine kinase, muscle strength and function, motor ner

232 s of serum cTnT, cTnI, creatine kinase (CK), creatine kinase myocardial band (CK-MB), and N-terminal

233 microg/l), and 1 equivalent to elevation of creatine kinase-myocardial band (1.5 ng/ml).

234 Creatine kinase-myocardial band (CK-MB) measurements wer

235 ention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with

236 The incidence of creatine kinase-myocardial band (CK-MB)-defined PPMI (CK

237 Elevation of creatine kinase-myocardial band after stenting occurred

238 ethodology to assess the association between creatine kinase-myocardial band and 1-year mortality.

239 The incidence of creatine kinase-myocardial band increases >3 times the u

240 Peak post-PCI creatine kinase-myocardial band was significantly associ

241 High-sensitivity cardiac troponin T and creatine kinase-myocardial band were measured before and

242 Creatine kinase-myocardial band yielded similar results,

243 me parameter was the area under the curve of creatine kinase-myocardial brain fraction concentration.

244 The area under the creatine kinase-myocardial brain fraction curve was 3144

245 arkers included high-sensitivity troponin T, creatine kinase, myoglobin, N-terminal B-type natriureti

246 n evident by a decrease in the expression of creatine kinase, myosin heavy chain-fast twitch, myogeni

247 o proceeded directly to phase B for elevated creatine kinase (N = 218, with 73 randomized to ezetimib

248 h large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, prob

249 There were no differences in creatine kinase or high sensitivity C-reactive protein l

250 Thirty-one of 34 patients had elevated creatine kinase or myoglobin.

251 at 3 months, or the area-under-the-curve for creatine kinase or troponin I.

252 nfarction </=1 flow, there was reduced serum creatine kinase (P=0.030) and a 19% reduction in cardiac

253 rapid ATP generation via the phosphocreatine-creatine kinase (PCr/CK) system, as a unique gene family

254 7 g/m(2) vs. 21 +/- 14 g/m(2); p = 0.01) and creatine kinase peak serum level (median [interquartile

255 Structural analysis of modified muscle-type creatine kinase peptide variants by two-dimensional NMR

256 letal muscle under the control of the muscle creatine kinase promoter (MCKcre mice) with mice having

257 e overexpressing PGC-1alpha under the muscle creatine kinase promoter (MPGC-1alphaTG mice) displayed

258 agged TEAD-1 under the control of the muscle creatine kinase promoter.

259 agged TEAD-1 under the control of the muscle creatine kinase promoter.

260 d reporter genes, including the myogenin and creatine kinase promoters, and by complete inhibition of

261 conversion of phosphocreatine to creatine by creatine kinase provides an essential chemical energy so

262 eatine kinase-MB (but not creatine kinase-MB/creatine kinase ratio) was higher with HBOC in moderate

263 osphorylation, anaerobic glycolysis, and the creatine kinase reaction were determined.

264 muscle anaerobic metabolism, the rate of the creatine kinase reaction, intracellular buffering of pro

265 is replenished from phosphocreatine via the creatine kinase reaction, we have now measured the creat

266 generation and ion transport, as well as the creatine kinase reaction.

267 Thus, creatine kinase reduces ADP-induced platelet activation.

268 No evidence of differences in creatine kinase release (P=0.92), troponin T (P=0.85), o

269 y (31)P nuclear MR spectroscopy, lactate and creatine kinase release spectrophotometrically, and hypo

270 e estimated by peak and area under the curve creatine kinase release was measured in all study popula

271 that the extent of infarct size measured by creatine kinase release was significantly associated wit

272 by late gadolinium enhancement sequences and creatine kinase release.

273 point was infarct size assessed by measuring creatine kinase release.

274 and increased aspartate aminotransferase and creatine kinase serum enzyme levels in cynomolgus macaqu

275 ed muscle degeneration and fibrosis, reduced creatine kinase serum levels, restored running capacity

276 This increase in creatine kinase should prompt studies examining the effe

277 Diagnosis using the classic blood marker creatine kinase sometimes yields unsatisfactory results

278 the phosphocreatine shuttle, where flagellar creatine kinase (Sp-CK) uses phosphocreatine to rephosph

279 Accordingly, endogenous plasma creatine kinase, studied in 9 healthy men (mean age 27.9

280 Atorvastatin also increased average creatine kinase, suggesting that statins produce mild mu

281 apacity of oxidative phosphorylation and the creatine kinase system to buffer the cellular ATP/ADP ra

282 to examine the bioenergetic reactions of the creatine-kinase system and the ATP synthesis/hydrolysis

283 es, including aspartate aminotransferase and creatine kinase, that are typically elevated as a result

284 We assessed whether the level of plasma creatine kinase, the enzyme that utilizes ADP and phosph

285 , the characteristic clearance properties of creatine kinase, the time course of muscle fiber regener

286 intra- and intermolecular cross-links within creatine kinase, then to map the interaction surfaces be

287 sterol, low-density lipoprotein cholesterol, creatine kinase, thyroid-stimulating hormones, and eryth

288 after rest, with a concomitant reduction of creatine kinase to normal values.

289 n, stabilized the sarcolemma, restored serum creatine kinase to wild-type levels, and protected muscl

290 olipoprotein A1 (apoA1), apoE, mitochondrial creatine kinase U-type, beta-synuclein, synaptogyrin-3,

291 No individual creatine kinase value exceeded 10 times normal, but aver

292 lower limb weakness with highly raised serum creatine kinase values (average 4500 IU/l) and frequent

293 Serum creatine kinase values were usually normal or slightly e

294 bout strength loss, less soreness, and lower creatine kinase values.

295 Creatine kinase was normal or mildly elevated.

296 r beta-actin, the cytosolic brain isoform of creatine kinase was the next most abundant bundle protei

297 tions of serum transaminases, bilirubin, and creatine kinase were infrequent and similar between grou

298 ion of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/F

299 erize the interaction between calmodulin and creatine kinase, which we identify as a novel calmodulin

300 tion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical